Abnormal expression of programmed cell death 5 gene in multiple myeloma patients.
- Author:
Li BAO
1
;
Guo-Rui RUAN
;
Xi-Jing LU
;
Xiao-Hui ZHANG
;
Jin LU
;
Ji-Hong NIU
;
Yao ZHANG
;
Min XIE
;
Ya-Zhen QIN
;
Ling-Di LI
;
Jin-Lan LI
;
Yan-Rong LIU
;
Shan-Shan CHEN
;
Xiao-Jun HUANG
Author Information
1. Peking University People Hospital, Peking University Institute of Hematology, Beijing 100044, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Aged;
Apoptosis Regulatory Proteins;
genetics;
Bone Marrow Cells;
pathology;
Case-Control Studies;
Female;
Gene Expression;
Humans;
Male;
Middle Aged;
Multiple Myeloma;
genetics;
pathology;
Neoplasm Proteins;
genetics;
Young Adult
- From:
Journal of Experimental Hematology
2010;18(3):634-637
- CountryChina
- Language:Chinese
-
Abstract:
The aim of this study was to investigate the gene expression of programmed cell death 5 (pdcd5) in plasma and bone marrow cells from patients with multiple myeloma (MM). Enzyme liked immunosorbent assay (ELISA) and real-time quantitative reverse transcription polymerase chain reaction (RQ-RT-PCR) were used to examine pdcd5 gene expression in plasma and marrow cells in 45 MM patients and 20 normal controls. The results showed that serum levels of PDCD5 protein in 45 MM patients were lower significantly compared with the normal controls and 20 responsive patients after chemotherapy, their plasma levels were (16.91 +/- 0.28) ng/ml, (19.11 +/- 0.29) ng/ml and (17.94 +/- 0.154) ng/ml respectively (p < 0.05). The pdcd5 gene expression levels detected by RQ-RT-PCR in 45 MM patients were lower significantly compared with the normal controls, their pdcd5 gene expression levels were 0.64 +/- 0.47 and 1.28 +/- 1.21 respectively (p < 0.05). It is concluded that the PDCD5 protein expression levels are low in patients with MM. These findings suggest that abnormal expression of pdcd5 may be involved in the pathogenesis of MM.
